Rachel E. Sanborn | Oncology | Portland, OR

A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies

Enrollment Status: Terminated

Publish Date: February 10, 2025

Intervention Type: Drug

Study Drugs: SEA-TGT, Pembrolizumab

Study Phase: Phase 1

A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 06, 2025

Intervention Type: Drug

Study Phase: Phase 1

LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Enrollment Status: Active_not_recruiting

Publish Date: January 30, 2025

Intervention Type: Drug

Study Drugs: Selpercatinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab

Study Phase: Phase 3

A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors

Enrollment Status: Active_not_recruiting

Publish Date: January 07, 2025

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Enrollment Status: Active_not_recruiting

Publish Date: November 29, 2024

Intervention Type: Drug

Study Drugs: Itacitinib, Osimertinib

Study Phase: Phase 1/Phase 2

An Open-Label Randomized Phase II Study of Combining Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor (TKI)-naïve Epidermal Growth Factor Receptor (EGFR)-Mutant Locally Advanced or Metastatic NSCLC

Enrollment Status: Active_not_recruiting

Publish Date: October 30, 2024

Intervention Type: Drug

Study Drugs: Osimertinib, Ramucirumab

Study Phase: Phase 2

A Phase II Study of Nivolumab Combined With Bicalutamide and Ipilimumab in Metastatic HER2-negative Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: October 26, 2024

Intervention Type: Drug

Study Drugs: Nivolumab, Ipilimumab, Bicalutamide

Study Phase: Phase 2

Phase 1/2 Study to Evaluate the Safety and Preliminary Activity of Nivolumab in Combination With Vorolanib in Patients With Refractory Thoracic Tumors

Enrollment Status: Completed

Publish Date: October 08, 2024

Intervention Type: Biological, Drug

Study Drugs: VEGFR/PDGFR Dual Kinase Inhibitor X-82, Nivolumab

Study Phase: Phase 1/Phase 2

A Phase 1, First-in-Human, Open-Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART® Protein Binding PD-1 and CTLA-4 in Patients With Unresectable or Metastatic Neoplasms

Enrollment Status: Active_not_recruiting

Publish Date: September 23, 2024

Intervention Type: Biological

Study Drug: MGD019 Bispecific DART Protein Binding PD-1 and CTLA-4

Study Phase: Phase 1

A Phase 1/2, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients with Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Previously Received Platinum-Based Systemic Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: September 19, 2024

Intervention Type: Drug

Study Drug: CLN-081

Study Phase: Phase 1/Phase 2

Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI0562) Administered Prior to Surgical Resection in Patients With Head and Neck Squamous Cell Carcinoma or Melanoma

Enrollment Status: Active_not_recruiting

Publish Date: August 23, 2024

Intervention Type: Drug

Study Drug: MEDI0562

Study Phase: Phase 1

A Phase Ib Study to Assess the Safety, Tolerability and Immunologic Activity of Preoperative IRX 2 In Early Stage Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: August 21, 2024

Intervention Type: Drug, Dietary supplement

Study Drugs: Cyclophosphamide, Indomethacin, Omeprazole

Study Phase: Phase 1

Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Melanoma

Enrollment Status: Active_not_recruiting

Publish Date: August 21, 2024

Intervention Type: Drug, Other

Study Drug: High-dose IL-2

Study Phase: Phase 2

A Phase 1 Study Investigating AGEN1777 as a Single-Agent and in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors

Enrollment Status: Completed

Publish Date: August 20, 2024

Intervention Type: Drug

Study Phase: Phase 1

Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Enrollment Status: Active_not_recruiting

Publish Date: August 20, 2024

Intervention Type: Drug

Study Drugs: X-396 (Ensartinib), Crizotinib

Study Phase: Phase 3

Neoadjuvant Immunoradiotherapy: Head & Neck Cancer (NIRT-HNC)

Enrollment Status: Active_not_recruiting

Publish Date: June 21, 2024

Intervention Type: Procedure, Drug, Radiation

Study Drug: Nivolumab

Study Phase: Phase 1/Phase 2

A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination With Pembrolizumab in Subjects With Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer

Enrollment Status: Completed

Publish Date: June 04, 2024

Intervention Type: Drug

Study Drugs: ADXS-503, Pembrolizumab

Study Phase: Phase 1/Phase 2

Phase 1b/II Trial of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies (Phase Ib) and Small Cell Lung Cancer Patients (Phase II) Who Have Progressed on Prior Platinum-based Chemotherapy

Enrollment Status: Completed

Publish Date: May 09, 2024

Intervention Type: Drug

Study Drugs: Carfilzomib, Irinotecan

Study Phase: Phase 1/Phase 2

A Phase I Study of GNX102 in Patients With Advanced Solid Tumors

Enrollment Status: Terminated

Publish Date: May 06, 2024

Intervention Type: Drug

Study Drug: GNX102

Study Phase: Phase 1

A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy

Enrollment Status: Active_not_recruiting

Publish Date: April 30, 2024

Intervention Type: Biological, Drug

Study Drugs: Tomivosertib, Pembrolizumab

Study Phase: Phase 2

A Phase 1, Open-Label Study of the Safety, Tolerability and Preliminary Clinical Activity of Allogeneic Invariant Natural Killer T (iNKT) Cells (agenT-797) as a Single Agent and in Combination With Approved Immune Checkpoint Inhibitors in Patients With Relapsed/ Refractory Solid Tumors

Enrollment Status: Completed

Publish Date: April 24, 2024

Intervention Type: Drug

Study Phase: Phase 1

Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors

Enrollment Status: Terminated

Publish Date: April 17, 2024

Intervention Type: Drug

Study Drug: Ladiratuzumab Vedotin

Study Phase: Phase 2

A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies

Enrollment Status: Completed

Publish Date: March 28, 2024

Intervention Type: Drug

Study Drugs: CDX-1140, CDX-301, Pembrolizumab, Gemcitabine, Nab-Paclitaxel

Study Phase: Phase 1

PTX35-001 A Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety of the Monoclonal Antibody PTX-35 in Patients With Advanced Solid Tumors Refractory to Standard of Care

Enrollment Status: Terminated

Publish Date: March 12, 2024

Intervention Type: Drug

Study Phase: Phase 1

A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pembrolizumab Plus Chemotherapy in Metastatic Triple Negative Breast Cancer Patients

Enrollment Status: Active_not_recruiting

Publish Date: February 22, 2024

Intervention Type: Drug

Study Drugs: Pembrolizumab, Paclitaxel, Capecitabine

Study Phase: Phase 1/Phase 2

Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI6469) Administered Prior to Definitive Surgical Resection Patients With Locoregionally Advanced, Oral Head and Neck Squamous Cell Carcinoma

Enrollment Status: Completed

Publish Date: February 07, 2024

Intervention Type: Drug, Procedure

Study Drug: MEDI6469 Anti-OX40 Antibody

Study Phase: Phase 1

A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors

Enrollment Status: Terminated

Publish Date: February 02, 2024

Intervention Type: Drug, Biological

Study Drugs: OSE2101, Docetaxel, Pemetrexed

Study Phase: Phase 3

Intratumoral Ipilimumab in Head and Neck Cancer

Enrollment Status: Active_not_recruiting

Publish Date: January 25, 2024

Intervention Type: Drug

Study Drug: Ipilimumab

Study Phase: Phase 1

Phase II Study of TGFβ Type I Receptor Inhibitor LY2157299 With Neoadjuvant Chemoradiation in Patients With Locally Advanced Rectal Adenocarcinoma

Enrollment Status: Active_not_recruiting

Publish Date: January 25, 2024

Intervention Type: Drug, Procedure

Study Drugs: LY2157299, Capecitabine, Fluorouracil

Study Phase: Phase 2

Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Renal Cancer

Enrollment Status: Active_not_recruiting

Publish Date: January 25, 2024

Intervention Type: Radiation, Biological

Study Drug: High Dose IL-2

Study Phase: Phase 2

A Phase I/II Study of MK-3475 With Gemcitabine in Patients With Previously-Treated Advanced Non-small Cell Lung Cancer (NSCLC)

Enrollment Status: Active_not_recruiting

Publish Date: October 26, 2023

Intervention Type: Drug

Study Drugs: MK-3475, Gemcitabine

Study Phase: Phase 1/Phase 2

A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The DURGA Trial)

Enrollment Status: Completed

Publish Date: September 21, 2023

Intervention Type: Biological, Drug

Study Drugs: Viagenpumatucel-L, Nivolumab, Pembrolizumab, Pemetrexed

Study Phase: Phase 1/Phase 2

A Phase I, First-in-human, Dose-escalation Study to Evaluate the Safety and Immunologic Response After Administration of HS-130 in Combination With HS-110 (Viagenpumatucel-L) in Patients With Solid Tumors Refractory to Standard Care

Enrollment Status: Completed

Publish Date: August 23, 2023

Intervention Type: Biological

Study Drugs: HS-110 (Viagenpumatucel-L), HS-130

Study Phase: Phase 1

Phase 2 Study - Evaluate the Clinical Activity of Tarloxotinib in Patients With Non-Small Cell Lung Cancer That Harbors an EGFR Exon 20 Insertion or HER2-Activating Mutation and Other Advanced Solid Tumors With NRG1/ERBB Family Gene Fusions

Enrollment Status: Terminated

Publish Date: June 28, 2023

Intervention Type: Drug

Study Drug: Tarloxotinib bromide

Study Phase: Phase 2

Ph1b/2 Open-Label,Multicenter Dose-Esc & Dose-Exp Study of Combo RMC4630 & Cobimetinib in Participants w/Relapsed/Refractory Solid Tumors & Ph1b Study of RMC4630 w/Osimertinib in Participants w/EGFR Mutation+,Locally Adv or Meta NSCLC

Enrollment Status: Completed

Publish Date: June 26, 2023

Intervention Type: Drug

Study Drugs: RMC-4630, Cobimetinib, Osimertinib

Study Phase: Phase 1/Phase 2

A Phase 1 Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies

Enrollment Status: Completed

Publish Date: June 18, 2023

Intervention Type: Drug

Study Drug: CDX-527

Study Phase: Phase 1

Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab in Patients With Metastatic Melanoma, Non-Small Cell Lung Cancer, and Head and Neck Squamous Cell Carcinoma.

Enrollment Status: Completed

Publish Date: June 05, 2023

Intervention Type: Drug

Study Drugs: Galactoarabino-Rhamnogalactouronate, Pembrolizumab

Study Phase: Phase 1

Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone

Enrollment Status: Completed

Publish Date: March 22, 2023

Intervention Type: Drug

Study Phase: Phase 2

A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

Enrollment Status: Terminated

Publish Date: September 21, 2022

Intervention Type: Drug, Dietary supplement, Biological

Study Drugs: Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Dexamethasone

Study Phase: Phase 2

Phase 1b/Study of VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer

Enrollment Status: Completed

Publish Date: May 02, 2022

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers

Enrollment Status: Completed

Publish Date: March 09, 2022

Intervention Type: Biological

Study Phase: Phase 1

Phase I/Ib Study of Surgical Resection or Radiofrequency Ablation (RFA) of Metastatic Lesions in the Liver in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Metastatic Colorectal Cancer

Enrollment Status: Terminated

Publish Date: February 14, 2022

Intervention Type: Drug

Study Drug: MEDI6469

Study Phase: Phase 1

A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)

Enrollment Status: Completed

Publish Date: November 04, 2021

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer

Enrollment Status: Completed

Publish Date: October 06, 2021

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Phase 1 Study of SGN-CD47M in Patients With Advanced Solid Tumors

Enrollment Status: Terminated

Publish Date: September 17, 2020

Intervention Type: Drug

Study Phase: Phase 1

A Phase 2 Study to Assess the Safety and Efficacy of Scalp Cooling Using PenguinTM Cold Caps for the Prevention or Reduction of Chemotherapy-induced Alopecia in Stage I-III Breast Cancer

Enrollment Status: Unknown

Publish Date: September 16, 2020

Intervention Type: Device

Study Phase: Not Applicable

A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

Enrollment Status: Completed

Publish Date: December 09, 2019

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGN-2FF in Patients With Advanced Solid Tumors

Enrollment Status: Terminated

Publish Date: July 19, 2019

Intervention Type: Drug

Study Phase: Phase 1

Phase I/II Study of Stereotactic Body Radiation Therapy to Metastatic Lesions in the Liver or Lung in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Progressive Metastatic Breast Cancer After Systemic Therapy.

Enrollment Status: Completed

Publish Date: March 21, 2019

Intervention Type: Biological

Study Phase: Phase 1

Dr. Rachel E. Sanborn

Overview

Insurance

Locations

Clinical Research

54 Clinical Trials

48 Total Publications

University Professional Services

University Professional Services

Providence Health And Services Oregon

Areas of Expertise